Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.44 |
| ▸ | CDK2 | P24941 | 6/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15718407 | 0.92 | PDE4D (0.42) | GSK3BCDK2 | |
| SCHEMBL17182908 | 0.91 | CDK2 (0.44) | GSK3BCDK2 | |
| SCHEMBL20627862 | 0.88 | TTK (0.40) | GSK3BCDK2MAPKAPK2 | |
| SCHEMBL17182815 | 0.87 | GSK3B (0.39) | GSK3BCDK2 | |
| SCHEMBL17182817 | 0.87 | GSK3B (0.39) | GSK3BCDK2 | |
| SCHEMBL17182832 | 0.87 | GSK3B (0.39) | GSK3BCDK2 | |
| SCHEMBL16729268 | 0.85 | TTK (0.42) | GSK3BCDK2 | |
| SCHEMBL17182965 | 0.85 | TTK (0.42) | GSK3BCDK2 | |
| SCHEMBL17182966 | 0.85 | TTK (0.42) | GSK3BCDK2 | |
| SCHEMBL1486090 | 0.81 | CSNK2B (0.48) | CDK2MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287077-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2024-08-29 | — | — | US | disclosed |
| US-20220204511-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2022-06-30 | — | — | US | disclosed |
| US-20220204511-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2022-06-30 | — | — | US | disclosed |
| US-20210009595-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2021-01-14 | — | — | US | disclosed |
| US-20210009595-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2021-01-14 | — | — | US | disclosed |
| US-10570143-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2020-02-25 | — | — | US | disclosed |
| US-10570143-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2020-02-25 | — | — | US | disclosed |
| US-20190322669-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2019-10-24 | — | — | US | disclosed |
| US-20190322669-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2019-10-24 | — | — | US | disclosed |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2019-02-07 | — | — | US | disclosed |
| US-9573954-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-21 | — | — | US | disclosed |
| US-9573954-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-21 | — | — | US | disclosed |
| EP-3068786-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | University Health Network (CA) | 2016-09-21 | — | — | EP | disclosed |
| US-20160137651-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2016-05-19 | — | — | US | disclosed |
| US-20160137651-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2016-05-19 | — | — | US | disclosed |
| US-20160137651-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2016-05-19 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
| WO-2015070349-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204511-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | DPYD, CYP3A5, CYP3A7 | GSK3B 3400/4885CDK2 1046/4885PTGER4 1342/4885 |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | GSK3B 3725/4885CDK2 1483/4885PTGER4 1249/4885 |
| US-20190322669-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | DPYD, CYP3A5, CYP3A7 | GSK3B 3875/4885CDK2 835/4885PTGER4 1112/4885 |
| US-20240287077-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | DPYD, CYP3A5, CYP3A7 | GSK3B 3400/4885CDK2 1046/4885PTGER4 1342/4885 |
| US-10570143-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | GSK3B 3725/4885CDK2 1483/4885PTGER4 1249/4885 |
| US-20210009595-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | DPYD, CYP3A5, CYP3A7 | GSK3B 3875/4885CDK2 835/4885PTGER4 1112/4885 |
| US-20160137651-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | DPYD, CYP3A5, CYP3A7 | GSK3B 3875/4885CDK2 835/4885PTGER4 1112/4885 |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | GSK3B 3890/4885CDK2 1430/4885PTGER4 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.